[Featured Stock] Deepnoid's Brain Aneurysm Imaging AI 'DeepNeuro' Receives Non-Covered Approval... 'Rising'

Deepnoid is on the rise. It appears that the news of the brain aneurysm brain imaging detection and diagnostic support software 'DEEP:NEURO' becoming eligible for clinical market entry as a non-reimbursable item has had an impact.

As of 2:16 PM on the 17th, Deepnoid was traded at 20,450 KRW, up 660 KRW (3.34%) compared to the previous trading day.

Deepnoid announced on the same day that it had been selected as an innovative medical technology. DEEP:NEURO was designated as an innovative medical device in March during the integrated review process for innovative medical devices. It was recognized for its technological innovation and market creation potential. After the final evaluation by the National Evidence-based Healthcare Collaborating Agency (NECA), it was selected as a final innovative medical technology.

With this selection, DEEP:NEURO can temporarily enter the clinical market as a non-reimbursable item. DEEP:NEURO assists medical professionals by AI interpreting and analyzing suspected brain aneurysm areas in brain vascular magnetic resonance angiography (MRA) images of patients suspected of having brain aneurysms.

Medical staff can use DEEP:NEURO as an interpretation support tool in clinical settings when confirming brain aneurysm results in brain vascular MRA. It is expected to improve the convenience and accuracy of image interpretation, enabling medical staff to respond quickly and preserve the golden time critical for treating cerebrovascular diseases.

This content was produced with the assistance of AI translation services.